|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Regulus Therapeutics Inc. (RGLS) |
|
|
$8.16 0.00 (0.00%) as of 4:30 Tue 6/24
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
1.19(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.97 - $8.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
81,610 |
85,610 |
| Total Buy Value |
$95,852 |
$95,852 |
$170,899 |
$178,179 |
| Total People Bought |
1 |
1 |
3 |
4 |
| Total Buy Transactions |
1 |
1 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
245,938 |
271,454 |
| Total Sell Value |
$0 |
$0 |
$310,668 |
$341,047 |
| Total People Sold |
0 |
0 |
4 |
4 |
| Total Sell Transactions |
0 |
0 |
7 |
10 |
| End Date |
2025-05-18 |
2025-02-14 |
2024-08-16 |
2023-08-17 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Papadopoulos Stelios |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(64,635) |
0 |
|
- |
|
| Papadopoulos Stelios |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(976,253) |
64,635 |
|
- |
|
| Rosen Hugh |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,292) |
0 |
|
- |
|
| Rosen Hugh |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,979) |
57,292 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(57,292) |
0 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(27,377) |
57,292 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,292) |
0 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,208) |
57,292 |
|
- |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(140,228) |
0 |
|
- |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(571,558) |
0 |
|
- |
|
| Witz Pascale |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(67,233) |
0 |
|
- |
|
| Klassen Preston |
President & Head of R & D |
• • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(115,555) |
0 |
|
- |
|
| Rastetter William H |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(57,292) |
0 |
|
- |
|
| Rastetter William H |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(44,264) |
57,292 |
|
- |
|
| Collier Kathryn J |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(75,565) |
0 |
|
- |
|
| Nunn Jason Raleigh |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(62,500) |
0 |
|
- |
|
| Baltimore David |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(57,292) |
0 |
|
- |
|
| Baltimore David |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,208) |
57,292 |
|
- |
|
| Baltimore David |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,292) |
0 |
|
- |
|
| Baltimore David |
|
– • – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,377) |
57,292 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(83,125) |
0 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2025-06-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,796) |
83,125 |
|
- |
|
| Collier Kathryn J |
|
– • – |
2025-06-17 |
4 |
OE |
$8.80 |
$46,240 |
D/D |
4,929 |
62,915 |
|
- |
|
| Collier Kathryn J |
|
– • – |
2025-06-16 |
4 |
OE |
$9.90 |
$13,820 |
D/D |
1,396 |
67,844 |
|
- |
|
| Klassen Preston |
President & Head of R & D |
• • – |
2025-06-03 |
4 |
B |
$7.99 |
$95,852 |
D/D |
12,000 |
48,055 |
0.01 |
2% |
|
176 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
